12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Clivatuzumab tetraxetan: Phase Ib data

Data from 53 evaluable metastatic pancreatic cancer patients who received >=2 prior therapies in an open-label Phase Ib trial showed that once-weekly 6.5 mCi/m 2 clivatuzumab for 3 weeks plus 200 mg/m 2 weekly gemcitabine for 4 weeks of a 4-week cycle led to a median overall survival (OS) of 119 days...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >